Literature DB >> 10989506

Geropharmacology for the rheumatologist.

L A Percy1, M A Fang.   

Abstract

Drug administration to older patients with rheumatic disease is a challenge because they are more likely to have adverse drug reactions compared with younger patients. Elderly patients are at risk for adverse drug effects because they often have multiple acute and chronic illnesses and are on several prescription and over-the-counter medications. This article will enhance the practitioner's understanding of how disease and age modulate the pharmacokinetics and pharmacodynamics of medications commonly prescribed for rheumatic disorders. Minimizing the number of drugs prescribed, starting medications at low doses and increasing slowly, and monitoring for toxicity are especially important in the elderly. With judicious use of medications, the quality of life of older patients with rheumatic disease can be enhanced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989506     DOI: 10.1016/s0889-857x(05)70150-2

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  4 in total

Review 1.  [Pharmacotherapy of rheumatic diseases in the aged].

Authors:  S Kary; F Buttgereit; G R Burmester
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743

Review 2.  Management issues with elderly-onset rheumatoid arthritis: an update.

Authors:  Ignazio Olivieri; Carlo Palazzi; Giovanni Peruz; Angela Padula
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Cyclodextrin-mediated gold nanoparticles as multisensing probe for the selective detection of hydroxychloroquine drug.

Authors:  Jaise Mariya George; Beena Mathew
Journal:  Korean J Chem Eng       Date:  2021-03-05       Impact factor: 3.309

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.